Efficacy of GCSF in Reducing Neutropenia in Cancer Patients
Author Information
Author(s): Kakar Maria, Ullah Sami, Khan Amjad, Naizir Shabnam
Primary Institution: Department of Pharmacy, University of Peshawar, Peshawar, Pakistan
Hypothesis
Does adjunctive GCSF therapy effectively reduce neutropenia in carcinoma patients undergoing chemotherapy?
Conclusion
Adjunctive GCSF therapy significantly benefits patients undergoing anticancer treatment by improving neutrophil recovery and reducing infections.
Supporting Evidence
- Patients receiving GCSF had a significant improvement in ANC recovery time.
- Better recovery of fever and fewer infections were observed in GCSF treated patients.
- 58.72% of patients received GCSF therapy, showing its effectiveness in managing neutropenia.
Takeaway
This study shows that giving GCSF helps cancer patients recover their white blood cells faster and stay healthier during chemotherapy.
Methodology
A prospective cohort study conducted at Hayatabad Medical Complex, evaluating clinical, hematological, and microbiological outcomes in patients receiving GCSF.
Potential Biases
Potential selection bias due to the single-center design and non-randomized assignment of GCSF treatment.
Limitations
The study was conducted at a single center and may not be generalizable to all populations.
Participant Demographics
Adult patients of both genders, primarily Pakistani (Pashtun), with a median age of 43.9 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website